Oramed Pharmaceuticals (ORMP) Operating Expenses (2011 - 2026)

Oramed Pharmaceuticals' Operating Expenses history runs 15 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• Quarterly Operating Expenses fell 18.92% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (down 0.59% YoY) and the FY2025 annual result came in at $15.1 million, up 18.15% from the prior year.
• Operating Expenses was $3.7 million for Q1 2026 at Oramed Pharmaceuticals, down from $5.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $11.8 million in Q4 2022 and bottomed at $2.4 million in Q3 2025.
• A 5-year average of $4.6 million and a median of $3.6 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses plunged 67.04% — and 2025, when it jumped 57.77%.
• Oramed Pharmaceuticals' Operating Expenses stood at $11.8 million in 2022, then plunged by 67.04% to $3.9 million in 2023, then slipped by 7.27% to $3.6 million in 2024, then soared by 57.77% to $5.7 million in 2025, then tumbled by 35.49% to $3.7 million in 2026.
• Business Quant data shows ORMP's Operating Expenses at $3.7 million in Q1 2026, $5.7 million in Q4 2025, and $2.4 million in Q3 2025.